Study of the role of local treatments on the modulation of the microbiome in psoriatic skin - Microbiome & Psoriasis Study

CHU de Nice0 个研究点目标入组 30 人开始时间: 2018年4月11日最近更新: 2019年4月30日

试验速览

暂无简介。

•1. Patients of both more than 18-year-old sexes having signed and dated a form of information and informed consent.
•2. Subject presenting a psoriasis vulgaris with symmetric hurts in size and in severity, located on elbows and\or knees and having a score of severity (PASI)< 10. The hurts will have to have a surface of at least 4 cms ².
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 28
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

•1. Subject presenting a psoriasis in drop(gout), érythrodermique, exfoliatif or pustuleux.
•2. Feminine Subject pregnant or breast-feeding.
•3. Subject having received a systematic treatment(processing) and having a potential action(share) on the psoriasis vulgaris (ex: phototherapy, cyclosporine, méthotrexate, biotherapics, steroids, or other immunosuppresseurs treatments(processings)) in 2 months preceding the randomization and during all the duration the study.
•4. Subject having received a treatment(processing) antibiotic in the previous three months the visit of inclusion
•5. Subject having received the topical treatments(processings) (example: corticostéroïdes, tazarotène, analogues of the vitamin D) or neutral emollients in 4 weeks preceding the randomization

发起方